





168Nephrin Loss Can Be Used to Predict
Remission and Long-term Renal Outcome
in Patients With Minimal Change DiseaseNina A. van de Lest1, Malu Zandbergen1, Daphne H.T. IJpelaar2, Ron Wolterbeek3,
Jan A. Bruijn1, Ingeborg M. Bajema1 and Marion Scharpfenecker1
1Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands; 2Department of Nephrology, Leiden
University Medical Center, Leiden, the Netherlands; and 3Department of Medical Statistics, Leiden University Medical Center,
Leiden, the NetherlandsIntroduction: Minimal change disease is a common cause of nephrotic syndrome. In general, patients with
minimal change disease respond to corticosteroids and have excellent long-term renal survival. However,
some patients have less favorable outcome. These patients are often thought to have progressed to focal
segmental glomerulosclerosis. We previously reported that a segmental loss of podocyte markers is
present before the development of focal segmental glomerulosclerosis in a rat model. Here, we investi-
gated whether loss of podocyte marker nephrin can serve as a biomarker for predicting poor outcome in
patients with minimal change disease.
Methods: We obtained 47 kidney biopsy samples from patients diagnosed with minimal change disease
and stained sections with periodic acidSchiff and for nephrin. Nephrin loss was scored by 2 independent
researchers who were blinded to clinical outcome. Clinical data were collected retrospectively, and
nephrin loss was correlated with clinical follow-up data.
Results: Nephrin loss was present in 34% of the biopsy samples. During follow-up, patients with nephrin
loss achieved remission less frequently (61%) compared to patients without (96%) (P ¼ 0.002). Moreover,
5-year eGFR was lower in the patients with renal nephrin loss. The risk of eGFR decreasing to < 60 ml/min
per 1.73m2 increased with each percentage of glomeruli with nephrin loss (hazard ratio ¼ 1.044, 95%
confidence interval ¼ 1.021.07).
Conclusion: These results indicate that nephrin loss in patients with minimal change disease can help
predict both remission and long-term renal outcome.
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inimal change disease (MCD) is a common
manifestation of nephrotic syndrome in both
children and adults.1 MCD is typically diagnosed by
examining a renal biopsy sample; few or no abnor-
malities are visible using light microscopy, but exten-
sive foot process effacement is observed using electron
microscopy.2 In general, patients with MCD respond
well to corticosteroids and have excellent long-term
patient and renal survival.3 However, the degree of
responsiveness to corticosteroids varies widely. In
addition, a substantial number of patients have poor
long-term outcomes, with frequent relapses andspondence: Nina A. van de Lest, Department of Pathology,
University Medical Center, Room P0-107, P.O. Box 9600,
C Leiden, the Netherlands. E-mail: n.a.van_de_lest@lumc.nl
ved 30 June 2017; revised 30 August 2017; accepted 18
mber 2017; published online 27 September 2017eventual renal impairment.3–7 Currently, no adequate
clinical parameters or biomarkers are available for
predicting clinical outcome and prognosis. Thus, to
provide patients a better prognosis and more targeted
therapies, a marker for predicting outcome is urgently
needed.
Patients with MCD who have a decline in renal
function occasionally have focal segmental glomerulo-
sclerosis (FSGS) in subsequent renal biopsy samples.5,8
Primary FSGS is another common manifestation of
nephrotic syndrome, and both primary FSGS and MCD
lie within the spectrum of podocyte injury-related
glomerular diseases. However, whether primary FSGS
represents an advanced stage of MCD is currently a
matter of debate.9,10 In support of this notion, patients
diagnosed with MCD based on their original biopsy
results have shown FSGS lesions in subsequent biopsy
samples.8,10–12 A similar course of events has beenKidney International Reports (2018) 3, 168–177
NA van de Lest et al.: Nephrin as Outcome Marker in MCD CLINICAL RESEARCHreported in renal transplant cases.11 The presence of
FSGS in a follow-up biopsy sample is usually associated
with unfavorable outcome, and these patients often
develop renal failure.8
We previously reported that the Munich Wistar
Frömter rat, a model for hereditary proteinuria and
glomerulosclerosis, has segmental loss of a molecule
important for podocyte integrity in rats prior to the
onset of FSGS.13 Interestingly, segmental loss of the
podocyte marker nephrin has also been reported in
patients with FSGS.14 However, whether nephrin loss
also occurred in nonsclerotic glomeruli was not
clarified.
Nephrin is a transmembrane protein located at the
podocyte slit diaphragm. In 1998, mutations in the
nephrin-encoding gene NPHS1 were identified in
children with congenital nephrotic syndrome of the
Finnish type.15 These mutations will lead to the
complete deletion or partial truncation of the protein,
and their identification revealed the key role of nephrin
in maintaining the glomerular filtration barrier.15 In
addition to its role in congenital nephrotic syndrome,
nephrin has also been studied in various acquired
nephrotic syndromes, including MCD.14,16–18 However,
the results are inconsistent; some studies reported a
downregulation of nephrin expression in MCD
compared to controls,16,17 whereas other studies
reported no apparent change in nephrin expres-
sion.14,18 These results raise the question of whether
these disparate findings could be due to differences in
disease course.
Given that loss of nephrin expression may reflect
podocyte injury prior to the onset of FSGS lesions, and
because the development of FSGS in patients with MCD
is associated with poor long-term outcomes, we tested
the hypothesis that segmental loss of nephrin in
patients with MCD could be used as an immunohisto-
logical biomarker for predicting outcome.METHODS
We retrospectively searched the archives of the
Department of Pathology at the Leiden University
Medical Center (LUMC) for renal biopsy samples of
patients who had biopsy-confirmed MCD and were
evaluated at the LUMC from 1985 through 2015. Pa-
tients were excluded if (i) the biopsy sample was ob-
tained from a transplanted kidney, (ii) the patient had
another underlying kidney disease, (iii) the biopsy
sample contained < 5 glomeruli or was otherwise
inadequate for evaluation, (iv) the patient had a viral
infection or had taken medication known to elicit
nephrotic syndrome, or (v) the patient did not have
nephrotic syndrome. Our initial search yielded 194Kidney International Reports (2018) 3, 168–177biopsy samples of patients with MCD. Biopsy samples
were then excluded for the following reasons: obtained
from a transplanted kidney (22 samples), comorbidity
(26 samples), insufficient tissue for analysis (48 sam-
ples), the patient did not have nephrotic syndrome (8
samples), no clinical data were available (39 samples),
or the biopsy was the second from a patient already in
our cohort (4 samples). Thus, a total of 47 patient bi-
opsy samples were included in the analysis.
As a control group, we used 12 kidney samples that
were obtained from Eurotransplant donors and were
not suitable for transplantation for technical reasons.
Clinical Data
Clinical data were extracted from the patients’ medical
records obtained from the hospitals at which the
patients were treated. We collected the patients’
clinical data at the time of biopsy, at approximately 1,
4, and 16 weeks of follow-up, and for up to 5 years of
follow-up. The following laboratory results were ob-
tained at the time of biopsy and approximately 1, 4,
and 16 weeks after the biopsy: estimated glomerular
filtration rate (eGFR; using the Modification of Diet in
Renal Disease formula for adults and the bedside
Schwartz formula for children), serum albumin (in g/l),
and proteinuria. In addition, we extracted information
on systolic and diastolic blood pressure (in mm Hg),
weight, height, sex, age, ethnicity, medication used at
the time of the biopsy, and whether a steroid trial had
been attempted before the biopsy.
We also collected follow-up data regarding remis-
sion, the recurrence of nephrotic syndrome (relapse),
therapy/prednisone resistance, therapy dependence,
and 5-year eGFR. Renal insufficiency and trans-
plantation were measured until the patient was lost to
follow-up, died, or received a transplant, or the study
period ended (on 31 December 2015). The medical
records were also used to identify cases in which
evidence of focal segmental glomerulosclerosis (FSGS)
appeared in a follow-up biopsy sample. Subanalyses of
clinical outcome were performed for patients < 18 of
age and for patients $ 18 years of age (Supplementary
Tables S1 and S2).
Endpoint Definitions
Nephrotic syndrome was defined as nephrotic range
proteinuria, serum albumin levels < 35 g/l, and edema.
Complete remissionwasdefinedasproteinuria< 0.3 g/24 h
and no proteinuria on dipstick or when clearly stated in
the medical records; partial remission was defined as a
reduction in proteinuria to 0.3 to 3.5 g/24 h.19
In the adult patients, hypertension was defined as
systolic blood pressure (SBP) > 140 mm Hg and/or
diastolic blood pressure (DBP) > 90 mm Hg, or the need169
CLINICAL RESEARCH NA van de Lest et al.: Nephrin as Outcome Marker in MCDfor hypertension medication to maintain a normal
blood pressure.20 In the pediatric patients, hyperten-
sion was defined as SBP and/or DPB values in
the $ 95th percentile for age, sex, and height or the
need for hypertension medication.21 Renal insuffi-
ciency was defined as eGFR < 60 ml/min. Steroid
dependence refers to relapse while on therapy or when
continuous treatment was needed to maintain remis-
sion. Steroid resistance refers to an insufficient reduc-
tion in proteinuria following a course of prednisone. A
relapse was considered to have occurred when stated in
the patient’s medical records after achievement of
remission.
Histology
Sequential sections (4-mm thickness) were cut from
paraffin-embedded samples using a Leica microtome.
The sections were stained with periodic acidSchiff
(PAS) using a standard protocol.
An experienced pathologist examined the
PAS-stained sections for the presence of mesangial
expansion, hyalinosis, synechiae (defined as single
cellular bridges),22,23 and global sclerosis (which can
also be seen in MCD and healthy control kidneys). In
the sections prepared for research purposes, 2 patients
had a lesion consistent with FSGS; because FSGS had
not been diagnosed in the routine diagnostics, these 2
biopsy samples were included for further analysis. Data
on electron microscopy were obtained from the
patients’ original pathology reports.
Immunohistochemistry
For each sample, a section adjacent to the PAS-stained
section was stained using a rabbit anti-nephrin anti-
body (ab58968; Abcam, Cambridge, UK). As a negative
control, a rabbit IgG-negative control fraction (Dako,
Glostrup, Denmark) was used at the same concentration
as the anti-nephrin antibody. Goat anti-rabbit EnVision
horseradish peroxidaseconjugated antibody (Dako)
was used as the secondary antibody, and staining was
visualized using diaminobenzidine as the chromogen.
The sections were counterstained with hematoxylin
and coverslipped with mounting medium.
To determine the presence of podocytes at the site of
nephrin loss, Wilms Tumor 1 (WT1) staining (sc-192;
Santa Cruz Biotechnology, Dallas, TX) was performed
on adjacent sections for biopsy samples with nephrin
loss.
Scoring of Staining Patterns
PAS- and nephrin-stained sections were scanned in an
Ultra-Fast scanner (Phillips Healthcare, Amsterdam,
the Netherlands). The sections were then scored by 2170observers who were blinded with respect to clinical
outcome. Loss of nephrin expression was scored for
all scorable glomeruli in each section. Loss of nephrin
was defined as > 10% interruption in the circum-
ferential nephrin staining surrounding the glomerular
tuft. A single nephrin-negative capillary loop was not
considered to be nephrin loss, as this was often seen
in healthy controls. Supplementary Figure S1 shows
examples of glomeruli with < 10% nephrin loss.
Nephrin-negative cellular adhesions of visceral and/or
parietal epithelial cells were also considered to indi-
cate nephrin loss, regardless of size. Consensus
between the 2 observers was reached by discussion.
Finally, the number of biopsy samples with nephrin
loss in at least 1 glomerulus was determined, and the
percentage of glomeruli with nephrin loss was
calculated. In addition, nephrin loss in glomeruli was
also scored semiquantitatively (Supplementary
Material). To determine whether nephrin loss was
not simply a surrogate marker for segmental sclerosis,
consecutive PAS-stained slides were used to examine
the presence of glomerulosclerosis at the site of
nephrin loss.
WT1 staining was assessed in all glomeruli with
segmental or global nephrin loss. Podocytes were
scored as present when WT1-positive cells were
detected at the exact site of nephrin loss.
Statistical Analysis
The Statistical Package for Social Sciences (SPSS)
version 23 (IBM, Armonk, NY) and Rstudio were used
for statistical analysis. Continuous variables were
compared between groups using the Student t test or
the MannWhitney U test and are expressed as the
mean  SD or as the median and interquartile range
(IQR). Categorical variables were compared using the
c2 test or Fisher exact test and are expressed as a
percentage. The development of hypertension at 5
years was analyzed using a z test for differences be-
tween proportions and reported as a cumulative per-
centage. The Spearman correlation was performed with
average nephrin loss score and continuous variables.
Cox regression analysis was used to analyze survival.
Because only 1 possible competing event was
observed, we did not calculate cumulative incidence
functions. A linear mixed model was used to analyze
whether the difference in proteinuria between patients
with and without nephrin loss was time point depen-
dent by evaluating the interaction term between
nephrin loss and time. For the linear mixed model,
proteinuria data were log transformed. The area under
the curve (AUC) for the percentage of glomeruli with
nephrin loss was calculated using the receiverKidney International Reports (2018) 3, 168–177
NA van de Lest et al.: Nephrin as Outcome Marker in MCD CLINICAL RESEARCHoperating characteristic (ROC) curve. For renal insuf-
ficiency, the corresponding Harrell C statistic was
calculated using the patients’ follow-up times, and the
patients’ XBETA-predictors calculated in the Cox
regression analysis.
Ethics Considerations
Tissue samples were collected during routine patient
care. For medical research purposes, the tissues were
coded and then handled anonymously in accordance
with the Dutch National Ethics Guidelines (Code for
Proper Secondary Use of Human Tissue).RESULTS
Glomerular Nephrin Expression and Renal His-
tology in Patients With MCD
We obtained 47 renal biopsy samples from patients
with MCD and 12 kidney samples from healthy
controls; these were then immunostained for nephrin.
As expected, control kidney sections had a linear
staining pattern for nephrin; this pattern followed
the glomerular basement membrane (Figure 1a and
Supplementary Figure S1). A similar pattern was
observed in biopsy samples obtained from patients
with MCD (Figure 1b); however, we also observed
glomeruli with either segmental (Figure 1c) or global
(Figure 1d) nephrin loss. In total, 34% of the patient
biopsy samples had nephrin loss in 1 or more glomeruli
(Figure 1e). With the exception of 2 glomeruli in 2
sections, nephrin loss was not co-localized with
glomerulosclerosis.
Next, we investigated whether podocytes were still
present at the site of nephrin loss. Staining sequential
sections for nephrin and the podocyte marker WT1
revealed WT1-positive staining at the site of nephrin
expression (Figure 1fh) but also at the site of nephrin
loss (Figure 1ik). In total, 82% and 66% of glomeruli
with global nephrin loss and segmental nephrin loss,
respectively, contained WT1-positive cells at the site of
nephrin loss, indicating that podocytes were still
present during nephrin loss.
To determine whether kidneys with nephrin loss
differed histologically from kidneys without nephrin
loss, we examined the PAS-stained sections; these
results are summarized in Table 1. We found that the
prevalence of global sclerosis, mesangial expansion,
and hyalinosis did not differ significantly between the
2 groups. Interestingly, we found synechiae in 2
biopsy samples with nephrin loss. An analysis of
electron microscopy data from the original pathology
report revealed that foot process effacement was similar
between the patients with nephrin loss and the patients
without nephrin loss.Kidney International Reports (2018) 3, 168–177Baseline Clinical Characteristics of the Patients
With and Without Nephrin Loss
Next, we looked for differences at time of biopsy
between patients with nephrin loss and patients
without nephrin loss by comparing the patients’ clin-
ical parameters; these results are summarized in
Table 2. We found no significant difference between
the 2 groups with respect to age, male-to-female ratio,
weight, eGFR, or degree of proteinuria. Moreover,
both systolic blood pressure and diastolic blood pres-
sure did not differ between the groups, both in chil-
dren and in adults, and the groups did not differ with
respect to the medications used. Finally, separate
analyses of nephrin loss in children and adults showed
that the prevalence of nephrin loss was similar
between patients < 18 years (31%) and patients >18
years (36%) of age (P ¼ 0.77).
To determine whether a steroid trial before biopsy
could have affected nephrin loss, we determined
whether patients had had a steroid trial before biopsy.
We found that 69% of children and 21% of adults had
had some sort of steroid trial before biopsy. The
percentages of nephrin loss were similar between
patients who did or did not have a steroid trial first
(29% vs. 36%, respectively; P ¼ 0.65).
Follow-up Characteristics and Response to
Therapy in Patients With Nephrin Loss and Pa-
tients Without Nephrin Loss
To determine the prognostic value of nephrin loss, we
first compared eGFR and proteinuria between the 2
groups after a 16-week period from the start of an
episode with nephrotic syndrome within which the
biopsy sample was taken. At the 16-week follow-up,
eGFR was similar between the groups, and linear
mixed model analysis revealed that the difference in
eGFR was not time point dependent. In contrast,
proteinuria was higher in the patients with nephrin
loss (1.0 g/24 h) compared to the patients without
nephrin loss (0.15 g/24 h) (P ¼ 0.02; Table 3). More-
over, linear mixed model analysis revealed that this
difference in proteinuria was time point dependent
(Pinteraction ¼ 0.04); thus, nephrin loss is associated
with higher proteinuria levels. The time course of
both proteinuria and eGFR is shown for each patient
in Figure 2.
Interestingly, we also found a significant difference
between the 2 groups with respect to remission rate.
Specifically, 96% of patients without nephrin loss
achieved remission, whereas only 61% of patients with
nephrin loss achieved remission (P ¼ 0.002) (Table 3).
In addition, we found a significant difference between
the 2 groups with respect to steroid resistance
(P ¼ 0.03) but not with respect to steroid dependence171
Figure 1. Normal nephrin staining pattern and nephrin loss in patients with minimal change disease. Nephrin-stained kidney sections from a
healthy control (a), a patient with minimal change disease (MCD) without nephrin loss (b), and 2 patients with MCD with nephrin loss (c,d).
Panels (a) and (b) show a normal linear pattern of nephrin staining along the glomerular basement membrane. In panels (c) and (d), nephrin loss
was either (c; arrowhead) segmental or (d) global. (e) Quantification of nephrin loss (defined as nephrin loss in at least 1 glomerulus) in the
biopsy samples obtained from patients with MCD. (f,i) To determine whether podocytes were still present at the site of nephrin loss, sections
with nephrin loss were stained for the podocyte marker Wilms Tumor 1 (WT1). Example images of WT1 (f,i), nephrin (g,j), and periodic
acidSchiff (h,k) staining in a patient without nephrin loss (fh) and a patient with nephrin loss (ik). Podocytes in glomeruli without nephrin
loss (fh) were WT1 positive (f, arrows) and nephrin positive (g, arrows). The presence of WT1-positive cells (i, arrowhead) at the site of
nephrin loss (j, arrowhead) indicates that podocytes were still present. Bar ¼ 50 mm.
CLINICAL RESEARCH NA van de Lest et al.: Nephrin as Outcome Marker in MCD(P ¼ 0.32). With respect to kidney function, the 5-year
eGFR values were lower in the patients with nephrin
loss (54 ml/min per 1.73 m2) compared to the patientsTable 1. Histologic and electron microscopy characteristics of the
patients with nephrin loss and the patients without nephrin loss
Characteristics Loss (n [ 16) No loss (n [ 31) P valuea
Global sclerosis, n (%) 5 (33) 3 (10) 0.10
Hyalinosis, n (%) 3 (20) 4 (13) 0.67
Mesangial expansion, n (%) 2 (13) 0 (0) 0.11
Synechiae, n (%) 2 (13) 0 (0) 0.11
Foot process effacement, n (%)b 14 (100) 25 (100) -
ac2 Test.
bIn 8 patients, electron microscopy data were not available or were of insufficient
quality.
172without nephrin loss (97 ml/min per 1.73 m2); however,
this difference was not statistically significant
(P ¼ 0.08). Moreover, patients with nephrin loss
developed renal insufficiency (defined as eGFR < 60
ml/min per 1.73 m2) faster compared to the patients
without nephrin loss (Figure 3). Cox regression analysis
revealed that the chance of developing renal insuffi-
ciency increased with each percentage of glomeruli
with nephrin loss (hazard ratio ¼ 1.044; 95% confi-
dence interval ¼ 1.021.07).
To determine whether the degree of nephrin loss in a
glomerulus might provide a better prediction of
clinical outcome, we also scored nephrin loss semi-
quantitatively. We analyzed this in 2 different manners.Kidney International Reports (2018) 3, 168–177
Table 2. Baseline clinical characteristics of the patients with
nephrin loss and the patients without nephrin loss
Characteristics Loss No loss P value
Age, yr, median (IQR) 33 (1458) 25 (940) 0.18a
Male:female, n 10:6 20:11 0.89b
Weight, kg, mean (SD)c 72 (21) 74 (35) 0.88
BP, mm Hg, mean (SD)e
Age < 18 yr
SBP 125 (10) 108 (11) 0.07d
DBP 75 (14) 64 (12) 0.24d
Age $ 18 yr
SBP 164 (31) 145 (27) 0.25d
DBP 89 (12) 83 (11) 0.30d
eGFR, ml/min per 1.73/m2, median (IQR)f 72 (50123) 89 (60153) 0.20a
Proteinuria, g/24 h, median (IQR)g 8.6 (5.514) 10 (7.013) 0.74a
Medication, n (%) 0.31b
No medication 1 (7) 0
Conservative treatmenth 4 (29) 4 (18)
Prednisone 9 (64) 15 (68)
Cyclosporine/cyclophosphamide/rituximab 0 (0.0) 3 (14)
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, inter-
quartile range; SBP, systolic blood pressure.
aMannWhitney U test for nonparametric variables.
bc2 Test.
cRespectively, n ¼ 12 and n ¼ 21.
dIndependent Student t test.
eRespectively, n ¼ 13 and n ¼ 21. Of the patients, 16 were <18 years and 31 patients
were $18 years of age, respectively.
fRespectively, n ¼ 13 and n ¼ 18.
gRespectively, n ¼ 9 and n ¼ 20.
hConservative treatment is defined as angiotensin-converting enzyme inhibitor or
diuretic use.
Table 3. Follow-up characteristics of the patients with nephrin loss
and the patients without nephrin loss
Characterstics Loss No loss P value
Remission, n (%) 0.002a
Complete 8 (61) 27 (96)
Partial 0 (0.0) 1 (4.0)
No remission 5 (39) 0 (0.0)
Proteinuria 16-week follow-up,
g/24 h, median (IQR)c
1.0 (0.192.4) 0.15 (0.00.21) 0.02b
eGFR 16-week follow-up, ml/min
per 1.73 m2, median (IQR)d
84 (64110) 88 (70114) 0.69b
Relapse, n (%) 5 (56) 22 (76) 0.40a
Steroid resistance, n (%) 4 (29) 1 (3.4) 0.03a
Steroid dependence, n (%) 9 (64) 14 (48) 0.32a
Transplantation, n (%) 1 (7.1) 0 (0.0) 0.34a
5-Year eGFR, ml/min per 1.73 m2,
median (IQR)e
54 (4297) 97 (78119) 0.08b
Nonhypertensive at 5 years (%)f 31 62 0.09g
FSGS at follow-up, n (%) 3 (20) 2 (7.4) 0.33a




cRespectively, n ¼ 7 and n ¼ 15.
dRespectively, n ¼ 11 and n ¼ 17.
eRespectively, n ¼ 5 and n ¼ 13.
fCumulative percentage free of events at 5-year time point.
gz Test for difference between 2 proportions.
NA van de Lest et al.: Nephrin as Outcome Marker in MCD CLINICAL RESEARCHFirst, the difference in “average nephrin loss score”was
determined for several clinical outcome characteristics
(Supplementary Table S3). This showed that patients
who did not achieve remission and patients who were
therapy resistant had a higher nephrin score, in linewith
the results of the dichotomous nephrin scoring. Also,
average nephrin loss correlated with proteinuria at 16
weeks (rho ¼ 0.51; P ¼ 0.016). Second, we categorized
patients based on the most affected glomerulus. Inter-
estingly, higher scoreswere significantly associatedwith
a failure to achieve remission (Supplementary Table S4)
(P < 0.001).Diagnostic Value of Nephrin Loss
Finally, to investigate the diagnostic value of nephrin
loss in biopsy samples obtained from patients with
MCD, we calculated the sensitivity, specificity, and
AUC values of nephrin loss in terms of remission and
the Harrell C statistic for development of renal
insufficiency. With respect to remission, the sensi-
tivity and specificity of nephrin loss were 78%
and 100%, respectively. The corresponding ROC
curve for the percentage of glomeruli with nephrin
loss showed an AUC of 0.89 (P ¼ 0.005). With respect
to renal insufficiency, the Harrell C statistic value
was 0.80.Kidney International Reports (2018) 3, 168–177DISCUSSION
In this study, we investigated whether nephrin loss in
a renal biopsy sample can be used to predict clinical
outcome in patients with MCD. We found that patients
with nephrin loss were less likely to achieve remission
compared to patients without nephrin loss. Strikingly,
we also found that 5-year eGFR was lower in patients
with nephrin loss, and we found that the risk of
developing renal insufficiency increased with the per-
centage of glomeruli with nephrin loss. Generally
speaking, patients with MCD often have a good clinical
prognosis and excellent renal survival. However, some
patients have an unfavorable clinical course, for
example, failing to respond to therapy and/or devel-
oping renal insufficiency or failure. Therefore, it is
important to find robust biomarkers to help clinicians
identify patients who are more likely to have an
unfavorable clinical response. Here, we report that
nephrin loss can help to distinguish between these 2
patient groups with respect to remission and renal
outcome. Assessing nephrin loss in a biopsy sample
may help clinicians identify patients who would likely
benefit from more rigorous follow-up care. Moreover,
nephrin loss may indicate that a prolonged course of
corticosteroids may not necessarily be recommended in
patients who do not respond to therapy.
On the other hand, although nephrin loss was
associated with therapy resistance, it was not associ-
ated with steroid dependence, nor was it associated173
Figure 2. Proteinuria and estimated glomerular filtration rate (eGFR) during short-term follow-up. Proteinuria was measured over time in each
patient with nephrin loss (a) and in each patient without nephrin loss (c). At 16 weeks, proteinuria was higher in the patients with nephrin loss
(1.0 g/24 h) compared to the patients without nephrin loss (0.15 g/24 h, P ¼ 0.02). Differences in proteinuria were associated with the time point
(linear mixed model, Pinteraction ¼ 0.04). (b,d) eGFR levels were similar between the patients with nephrin loss (b) and the patients without
nephrin loss (d; P ¼ 0.69).
CLINICAL RESEARCH NA van de Lest et al.: Nephrin as Outcome Marker in MCDwith relapse. Taken together, these results indicate that
detection of nephrin loss can help identify patients
with a more chronic disease course, but may not help
identify patients with frequent relapses and/or a fluc-
tuating disease course.
We found that the average nephrin score, based on
the degree of nephrin loss in all the glomeruli in aFigure 3. Renal insufficiency in minimal change disease patients
with nephrin loss. KaplanMeier survival curve depicting renal
insufficiency in patients with nephrin loss and patients without
nephrin loss. Renal insufficiency developed earlier in the patients
with nephrin loss compared to the patients without nephrin loss.
Moreover, the likelihood of developing renal insufficiency increased
with every percentage of glomeruli with nephrin loss, as shown by
Cox regression analysis (hazard ratio ¼ 1.04, 95% confidence in-
terval 1.021.07).
174biopsy sample, led to the same conclusions compared to
the dichotomous scoring based on the presence or
absence of nephrin loss. This indicates that the simpler
dichotomous scoring is sufficient to assess nephrin loss,
which makes translation into clinical practice easier.
Interestingly, we found that the results of the scoring
based on the highest score of nephrin loss in a
glomerulus was more strongly correlated with
achieving remission compared to the dichotomous
classification. This finding suggests that using a
different cut-off value for the dichotomous classifica-
tion may further improve the predictive value of
nephrin loss. Future studies should examine this in
further detail using a larger patient cohort.
A potential limitation of our study is that some of
the patients with nephrin loss may have had FSGS all
along and were missed during routine diagnostics due
to sampling error. All of the patients in our study were
diagnosed with MCD; however, we cannot exclude the
presence of FSGS lesions due to a sampling error.
Accordingly, 2 of our patients had segmental lesions
that were identified only after the biopsy sample was
sectioned further for research purposes; these lesions
were not present in the original slides prepared for
routine diagnostics. Both of these patients also had
extensive segmental nephrin loss in unaffected
glomeruli. Therefore, in addition to indicating poor
outcome, nephrin loss may also indicate a missed
diagnosis of FSGS. Nevertheless, finding nephrin loss
in the same biopsy sample used for diagnostic purposes
provides additional information regarding the patient’sKidney International Reports (2018) 3, 168–177
NA van de Lest et al.: Nephrin as Outcome Marker in MCD CLINICAL RESEARCHprognosis, regardless of whether sampling error had or
had not occurred. It is important to note that because
nephrin loss does not affect all glomeruli in a section,
sampling error of nephrin loss should still be consid-
ered when using nephrin loss as an immunohistological
biomarker.
Another limitation of our study is that the biopsy
samples were taken at different time points. Especially
in children, biopsy samples are sometimes taken later
in the disease course and not during the first episode of
nephrotic syndrome, in which a steroid trial is often
already attempted. However, in our study, 69% of
children and 21% of adults had steroids before renal
biopsy, and nephrin loss was similar between patients
who did or did not have a steroid trial first. Therefore,
our data do not support the notion that steroids affect
nephrin loss.
In addition, our cohort contained both adults and
children, and clinical response can differ between
children and adults with MCD.24 We observed a similar
rate of nephrin loss between the children and adults.
Separate subanalyses of the children and adults
revealed similar trends with respect to renal function
and response to therapy, although nephrin loss
appeared to have a greater effect on response to therapy
among the children, as 75% of pediatric patients with
nephrin loss did not achieve remission (Supplementary
Table S1). Nevertheless, it is difficult to draw definite
conclusions, as our study lacked sufficient power for
such an analysis. Therefore, differences in the prog-
nostic value of nephrin loss between different age
categories of patients with MCD should be investigated
in future studies.
In our study, we found that nephrin loss is associ-
ated with poor renal outcome. With respect to patho-
physiology, it would be interesting to determine
whether poor outcome was due to podocyte loss and/or
the selective loss of nephrin. In our staining experi-
ments, we found WT1-positive podocytes to be pre-
sent at the site of nephrin loss. Given that MCD is
considered a podocytopathy and is characterized by
extensive podocyte foot process effacement, nephrin
loss in MCD might be indicative of more severe
podocyte damage. Although foot process effacement in
MCD is generally considered to be reversible, irre-
versible foot process effacement is believed to underlie
the development of glomerulosclerosis.25 The point at
which foot process effacement becomes irreversible is
currently unknown; however, in animal studies, both
the dose and exposure duration to the compound
causing podocyte damage have been suggested as
contributing factors.26 It is believed that loss of
podocytes following prolonged stress and the subse-
quent formation of adhesions between the glomerularKidney International Reports (2018) 3, 168–177filtration barrier and Bowman capsule (synechiae) play
a major contributing role in the formation of sclerotic
lesions.27 Consistent with this notion, we found
synechiae in 2 patients with nephrin loss, which is
indicative of the early development of a segmental
sclerotic lesion.
Several mechanisms of nephrin loss have been
described. For example, in vitro experiments showed
nephrin shedding from podocytes under diabetic
conditions.28 In patients with diabetic nephropathy,
nephrin can be detected in the urine, and urinary
nephrin levels are correlated with renal traits.29 Menne
et al. reported that nephrin loss, but not the loss of
other slit-pore proteins, is mediated by protein kinase
Ca in experimental diabetic nephropathy.30 Nephrin
shedding has also been studied in preeclampsia. For
example, Collino et al. reported that nephrin shedding
is induced by endothelin-1 produced by endothelial
cells after incubation with patient sera.31 Moreover,
nephrin loss was also observed after in vitro stimulation
of podocytes with serum obtained from patients with
FSGS.32 This suggests that in MCD, nephrin loss may
also be due to nephrin shedding, possibly induced by a
factor derived from patient serum.
If nephrin loss in MCD is caused by shedding,
nephrin should be detectable in the urine. Indeed,
urinary nephrin has been studied as a biomarker for
early renal complications in several diseases.29,33–35
Importantly, measuring urinary nephrin is noninva-
sive and can be performed repeatedly, thereby
reducing sampling error. Thus, urinary nephrin should
be explored as a possible biomarker for predicting
long-term outcome.
In conclusion, we report that nephrin loss in renal
biopsy samples obtained from patients with MCD can
be used to predict the patients’ response to therapy, the
likelihood of achieving remission, and long-term renal
outcome, thereby supporting the use of nephrin as a
biomarker in MCD.DISCLOSURE
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